BridgeMD
Personalized dosing of ocrelizumab in MS
EU CTIS ID: 2024-513193-22-00
What this study is testing
With this study we aim to prove that personalized B cell tailored ocrelizumab treatment is non-inferior in the suppression of MS disease activity compared to the standard (fixed 24 week interval) treatment.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- A current diagnosis of relapsing remitting multiple sclerosis according to the 2017 McDonald criteria
- Age of 18 or older
- EDSS score of 0 to 6.5 inclusive
- Treatment with ocrelizumab for a minimum of 48 weeks (two 300 mg infusions and one 600 mg infusion)
- Last ocrelizumab interval not extended, maximum of 7,5 months between the infusions
You likely can't join if
- Previous treatment with alemtuzumab, cladribine or stem cell transplantation
- Relapse in the past 3 months prior to inclusion
- Subsequent treatment with another DMT next to ocrelizumab in the past 6 months prior to inclusion
- Inability to undergo regular MRI scanning
- Women who are pregnant or expect to become pregnant during the study period
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.